Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab

About this information

This information explains the evidence summary about the off-label use of rituximab for minimal change disease and focal segmental glomerulosclerosis. The evidence summary is an overview of the available information about this medicine. It aims to help prescribers and patients when they are considering whether or not to use an unlicensed or off-label treatment. The summary does not contain recommendations from NICE on whether the medicine should be used.